CRO Selects CTMS Solution for Global Complex Clinical Trial Support
BioClinica®, Inc. announced a new agreement with Cato Research Ltd., a full-service contract research organization. Cato Research selected BioClinica’s clinical trial management system (CTMS) platform in its search for a best-in-class solution to better serve its growing worldwide client base.
“BioClinica is pleased to be selected by Cato Research for its clinical trial management needs after such an indepth selection process,” said Peter Benton, President of BioClinica’s eClinical division. “We have seen a significant increase in customer interest in our CTMS solutions because these solutions provide the scalability needed to support global research and the flexibility sponsors need to create more efficient eClinical environments.”
CTMS applications help to manage business and operational processes for clinical trials by capturing and manipulating the trial data electronically. BioClinica’s CTMS capabilities include applications to manage data related to clinical sites, personnel, subjects, and clinical supplies; scheduling, tracking, and monitoring performance; site payments; study document management; vendors; and more. BioClinica Office-Smart Clinical Trial Manager (Office-Smart CTMS) is supported by Microsoft SharePoint and BioClinica technologies to provide team collaboration, connectivity, and efficiency in a multisite environment. With its ClinBUS Connector, BioClinica’s CTMS interfaces with a variety of systems, such as electronic data capture and interactive voice or web response systems, to allow full integration of all clinical data.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
